First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Béla Ózsvári; Federica Sotgia; Michael P. Lisanti

doi:doi:10.18632/aging.103336

← Back

Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 14. A large mito-ribosome gene signature predicts overall survival in ER(-)/basal breast cancer patients. In ER(-)/basal breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict overall survival in N=153 patients (HR=3.17; P=0.00033).